Introduction 

An overview of lysosomal storage diseases

Lysosomal storage diseases (LSDs) describe a group of rare inherited disorders, affecting how the body breaks down certain substances within cells, such as fats and sugars. There is a component of the cell machinery called the lysosome, which helps digest and break down cellular debris, that fails to function properly in these LSDs. This is often due to absent or malfunctioning enzymes, caused by genetic mutations. This can result in the buildup of macromolecules (bigger molecules) and waste materials, triggering inflammation and cellular damage.

The nervous system, particularly the brain, is often affected in these disorders, with the damage usually being irreversible.¹

LSDs typically occur during pregnancy or shortly after birth, affecting approximately 1 in 8000 newborns.² Most of the LSD are inherited in an autosomal recessive manner, except for Fabry disease and mucopolysaccharidosis, which show X-linked recessive inheritance instead.

The role of lysosomes and enzymes in cell health

Lysosomes and enzymes play a vital role in keeping our cells healthy and functioning properly. Lysosomes are small, membrane-bound structures inside cells that act like waste disposal and recycling units. They contain a variety of enzymes, which are specialised proteins that facilitate and speed up chemical reactions, such as in the process of food digestion. These enzymes are responsible for breaking down complex molecules such as fats, proteins, and sugars into smaller, usable parts that can be absorbed by the body. The cell can then reuse these parts for energy and repair.³

This process is essential, and without it, waste materials and byproducts accumulate and interfere with the cell’s normal functions. 

In LSDs, where this process is interrupted due to a lack of lysosomal enzymes, macromolecules (big molecules) and other substances build up within lysosomes, causing severe damage. These effects are particularly critical when they impact the central nervous system, because of the vast and wide-reaching role it has in controlling movement, cognition, and other essential functions. 

How LSDs affect the brain and nervous system

LSDs can often have a profound impact on the brain and nervous system. As waste materials accumulate and nerve cells begin to become damaged or die, a range of neurological symptoms can arise. These include:

• Developmental delays⁴
• Seizures⁴
• Difficulty with movement and coordination⁴
• Vision loss⁴
• Cognitive decline⁴

Most LSDs are progressive, which means that symptoms tend to worsen over time as more brain tissue is affected. Since neurons are highly sensitive, neurological manifestations of LSDs are usually more severe and irreversible.⁴

Why brain imaging is crucial in diagnosing LSDs

Brain imaging tools play a key role in diagnosing LSDs, especially those that affect the central nervous system. Techniques like magnetic resonance imaging (MRI) and Computerised Tomography (CT) scans allow doctors to see structural changes in the brain, such as tissue abnormalities, atrophy (brain shrinkage), or specific patterns linked to certain LSDs. These visual clues can help distinguish LSDs from other neurological conditions and improve our understanding of the condition, which may suggest more avenues for diagnosis, like further genetic testing for the specific type of damage. Imaging is also valuable for tracking disease progression over time and monitoring how the brain responds to treatments.

Overview of imaging techniques used

There are a number of imaging techniques used in diagnosing LSDS. Read on for an overview of some of the main imaging tools used.

Magnetic Resonance Imaging (MRI)

An MRI scan is a technique that uses powerful magnets and radio waves to form detailed pictures of the inside of the body. It can be used to image organs, tissues, and bones clearly without using X-rays. MRI scans are commonly used to diagnose conditions affecting the brain, spine, joints, and soft tissues. Specialised functional MRIs can even be used to measure the metabolic rate of brain tissues over time. The process is painless and non-invasive, providing valuable information for accurate diagnosis and treatment planning.

Computerized Tomography (CT)

A CT scan is a tool that uses X-rays to create highly detailed cross-sectional images of the body using an advanced computer. It provides more detailed information than a regular X-ray, allowing for a close look at bones, organs, blood vessels, and soft tissues with clarity. CT scans are commonly used to detect injuries, infections, tumors, and internal bleeding. The procedure is quick, painless, and non-invasive, making it useful and efficient. Some patients may be required to receive a contrast dye to enhance the images. 

Positron Emission Tomography (PET)

A PET scan goes further than still images and shows how organs and tissues are functioning in the body. It involves injecting a small amount of radioactive tracer, often a type of glucose (a sugar), which moves through the body and is taken up in areas with high metabolic activity, which is often a characteristic of disease. The scanner detects this activity and creates detailed, color-contrasted images. PET scans are commonly used to detect cancer, evaluate brain disorders, and assess heart function. They can identify abnormalities earlier than other imaging tests by revealing changes in metabolic activity outside of the normal range. PET scans are often combined with CT or MRI scans to provide more complete diagnostic information for treatment planning.

Common brain changes seen on imaging

Demyelination (white matter abnormalities)

In many LSDs that affect the brain, MRI scans often show changes in the cerebral white matter, referred to as leukodystrophy. This part of the brain is called white matter because it contains myelinated axons, which are the insulated components of nerve cells that help speed up the transmission of electrical signals to send messages quickly between different regions in the brain. Myelin is produced by specialised brain cells called oligodendrocytes. These areas usually appear darker on MRI scans, but in the presence of demyelinating diseases, white matter can appear unusually bright. ⁴ This may be due to the characteristic accumulation of toxic material that is seen in LSDs, which can disrupt oligodendrocyte action, either preventing white matter from developing properly or causing it to break down.^4,5

These white matter changes are common in subtypes of LSDs like Krabbe disease and metachromatic leukodystrophy.⁴ Doctors can use these MRI patterns to help identify the specific disease and monitor its progression.

Brain atrophy

Brain atrophy means that parts of the brain are shrinking or losing volume. In LSDs that affect the nervous system, MRI scans often show that the brain's outer layer, known as the cortex, and deeper areas are getting smaller over time.⁶ This can be identified on an MRI by an expansion of the fluid-filled cavities of the brain (called ventricles) and as more space between the folds of the brain. It is commonly found in people with Alzheimer's disease and other neurodegenerative disorders. 

Some diseases affect specific areas, like the cerebellum, which controls movement and balance, or the brainstem, which manages vital functions.⁶ This loss of brain tissue happens because storage material builds up in cells and damages them. The amount of shrinkage usually matches how severe a person’s symptoms are, such as memory loss, difficulty walking, or poor coordination.⁴

Deep gray matter changes 

The basal ganglia and thalamus are deep parts of the brain that help control movement and process external sensory signals. In some LSDs, these areas are affected by the buildup of harmful substances. On MRI scans, they may look darker or brighter than normal, particularly the globus pallidus, a component of the basal ganglia.⁷ The brightness of the image may depend on what’s accumulating, such as fats, iron, or calcium.⁶ These changes are often seen in diseases like Fucosidosis, Tay-Sachs, Sandhoff, and Niemann-Pick type C.^4,7 When these deep brain structures are damaged, people can develop movement problems such as muscle stiffness, tremors, or seizures, and because these patterns are relatively unique, they can help distinguish LSDs from other brain disorders.

Ventricular enlargement and hydrocephalus (Extra fluid in the brain)

In many cases of LSDs, MRI scans show enlarged ventricles, which are spaces in the brain filled with cerebrospinal fluid (CSF), a colourless liquid responsible for protecting and cushioning the brain and spinal cord.¹ This often happens because brain tissue has shrunk due to demyelination, leaving more room for fluid, a condition known as ex vacuo enlargement.^1,4 

In some LSDs, like mucopolysaccharidoses, different abnormalities have been observed. In these cases, CSF drainage is disrupted, leading to a buildup of fluid, resulting in a condition called communicating hydrocephalus.⁹ This can cause pressure in the brain, worsening symptoms like headaches, balance issues, or trouble thinking clearly. Recognising this on imaging is important because it can sometimes be treated by inserting a small tube (a shunt) to relieve the pressure. In these cases, timely intervention can improve quality of life.

Catching these changes early is important because they often reflect how severe the disease is and can help guide treatments like enzyme therapy or stem cell transplants.

Post-diagnosis and treatment

Treatment of LSDs after diagnosis focuses on reducing the buildup of toxic substances, managing symptoms, and improving quality of life. 

Enzyme replacement therapy (ERT) is currently the cornerstone for several LSDs, such as Gaucher, Fabry, and Pompe disease. ERT involves intravenous infusions of synthetic, fully functional forms of enzymes to replace the deficient or impaired ones.¹⁰ Additionally, in vivo gene therapy is also offered, which consists of a direct viral vector injection, encoding for the functional enzyme of interest.¹⁰

Substrate reduction therapy (SRT) is another option that reduces the production of substances accumulate due to enzyme deficiency.¹¹ This focuses on inhibiting enzymes associated with the synthesis of substrates that can contribute to toxic buildup within cells. This can ultimately reduce the overall storage burden within lysosomes, restore balance, and delay disease progression.¹¹ However, a key limitation is that it relies on the presence of some enzyme activity in affected cells, so it may be less effective in more severe cases of LSDs. 

Hematopoietic stem cell transplantation (HSCT) may also be beneficial in some severe forms, such as Hurler syndrome, especially if performed early. Cells derived from donors that can produce functional enzymes are administered, which can migrate to the brain and delay neurocognitive degeneration.¹⁰ However, HSCTs have a high risk of infections and rejections from the body, which can contribute to a higher mortality rate in patients.¹⁰

Further research, utilising multidisciplinary teams involving genetics, neurology, and metabolic specialists, is essential for personalized care and long-term monitoring. Early diagnosis and timely intervention significantly improve clinical outcomes for patients.

Summary 

• Lysosomal Storage Diseases (LSDs) are rare genetic disorders caused by faulty enzymes that prevent cells from breaking down waste materials properly 
• This buildup of toxic substances can damage many parts of the body, especially the brain and nervous system
• The nervous system is especially vulnerable to LSDs. As the disease progresses, symptoms like developmental delays, seizures, cognitive decline, and movement problems often worsen over time
• Brain imaging is a key diagnostic tool. Techniques like MRI, CT, and PET scans help detect structural and functional changes in the brain. These images can show patterns specific to certain LSDs and are useful for monitoring disease progression and treatment effectiveness
• White matter changes (demyelination) are common in LSDs. Myelin, the protective coating around nerve fibers, can be disrupted by toxic buildup, slowing brain communication. This is often seen as bright spots on MRI and helps identify diseases like Krabbe or metachromatic leukodystrophy
• Other imaging signs include brain shrinkage (atrophy), abnormal signals in deep brain regions like the basal ganglia, and enlarged fluid spaces (ventricles). These changes reflect damage to brain structures and can explain symptoms like poor coordination, stiffness, or memory loss
• Treatments aim to slow progression and improve quality of life. Options include enzyme replacement therapy (ERT), substrate reduction therapy (SRT), gene therapy, and stem cell transplants. Early diagnosis and personalized care greatly improve patient outcomes